A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia

Leukemia

Volumn 28, Issue 7, 2014, Pages 1570-1572

  Drummond, M W ^a   Pocock, C ^b   Boissinot, M ^c   Mills, J ^d   Brown, J ^c   Cauchy, P ^d   Cross, N C P ^e   Hartley, S ^c   Kell, J ^f   Szubert, A ^c   Cockerill, P N ^d   Bowen, D T ^g  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^g St James's Institute of Oncology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CBL PROTEIN; TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; BLOOD TOXICITY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; DNA METHYLATION; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LETTER; LEUKOCYTOSIS; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ONCOGENE N RAS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84904070660     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.85     Document Type: Letter

References (13)

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes a randomised, open-label, phase III study. Lancet Oncol 2009 10 223-232.
2. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL et al. Approval summary azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005 11 3604-3608.
3. Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, Zenati M et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011 117 2690-2696.
4. Thorpe M, Montalvao A, Pierdomenico F, Moita F, Almeida A. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine a case series and literature review. Leuk Res 2012 36 1071-1073.
5. Ades L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res 2013 37 609-613.
6. Cheson B, Greenberg P, Bennett J, Lowenberg B, Wijermans P, Nimer S et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006 108 419-425.
7. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn. IARC Press Lyon, France, 2008.
8. Wattel E, Guerci A, Hecquet B, Economopoulos T, Copplestone A, Mahe B et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood 1996 88 2480-2487.
9. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009 113 6182-6192.
10. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010 42 722-726.
11. Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, Ward D et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 2012 119 1208-1213.
12. Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia a phase 2 trial. Blood 2011 118 3824-3831.
13. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007 109 52-57.